Advertisement
News
Subscribe to MDT Magazine News

New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions

April 13, 2011 5:36 am | by Bio-Medicine.Org | Comments

IRVINE, Calif., April 13, 2011 /- Two new studies published in the current issue of Surgery for Obesity and Related Diseases, a peer-reviewed journal, add to the large body of scientific evidence which supports that the LAP-BAND® Adjustable Gastric Banding System, made by Allergan,...

TOPICS:

ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)

April 13, 2011 5:36 am | by Bio-Medicine.Org | Comments

DALLAS, April 13, 2011 /- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced that data related to wound management will be presented at the 24th Annual Symposium on Advanced Wound Care and Wound Healing...

TOPICS:

Taris Biomedical rounds up $18.3M in Series B financing

April 13, 2011 5:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Taris Biomedical, a Lexington life sciences company developing combination drug-device products and co-founded by Michael Cima and Robert Langer, has taken in $18.3 million in a Series B funding round led by new investor Third Rock Ventures.

TOPICS:
Advertisement

GE Healthcare Presents Interim Data on the Impact of DaTscanâ„¢ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Un...

April 13, 2011 5:33 am | by Bio-Medicine.Org | Comments

HONOLULU, April 13, 2011 /- Today, GE Healthcare announced interim results of a recently completed randomized study of the impact of DaTscan™ SPECT imaging on the clinical  management and diagnosis of adult patients who exhibit signs or symptoms of parkinsonian syndromes (PS)....

TOPICS:

Medyssey Spine Receives 510(k) Clearance for Its LP Cage(TM) Posterior Lumbar Interbody Fusion System

April 13, 2011 3:37 am | by Bio-Medicine.Org | Comments

CHICAGO, April 13, 2011 /- Medyssey Co., Ltd., the parent company of Medyssey Spine , a spinal implant manufacturer focused on commercializing products for the surgical treatment of spine disorders, today announced that the Company has received 510(k) clearance from the FDA for its LP...

TOPICS:

According to the Journal of Advanced Nursing, RyMed Technologies' InVision-Plus® Excels at Minimizing Bacterial Growth In Vitro

April 13, 2011 3:34 am | by Bio-Medicine.Org | Comments

FRANKLIN, Tenn., April 13, 2011 /- In the Journal of Advanced Nursing March issue, a comparative research evaluation of five needleless I.V. connectors tested by an independent laboratory showed that the RyMed InVision-Plus® (RYM-5001®) zero displacement connector best protected...

TOPICS:

Mass. state agencies, local companies shoot to make a splash at BIO show

April 12, 2011 8:41 pm | by Mass High Tech: The Journal of New England Technology | Comments

Massachusetts state officials, industry groups, life sciences companies and educational institutions will have a dual purpose when they go to the BIO International Convention in Washington, D.C., in June. They will be promoting the 2012 version of BIO, which will be returning to Boston,...

TOPICS:

Speeding Up the Healing Process

April 12, 2011 8:39 pm | by Massachusetts Institute of Technology | Comments

New agents could help the body repair chronic wounds, and make the normal healing process work more quickly.

Advertisement

Retired Aetna CEO exercised $50M in stock options

April 12, 2011 12:45 pm | by TOM MURPHY - AP Business Writer - Associated Press | Comments

Aetna's retired CEO Ronald Williams gave himself a lucrative farewell last year by exercising stock options worth more than $50 million.The 61-year-old executive also received a compensation package totaling $18.4 million from Aetna and heads into retirement with a pension valued at $9.5 million...

Investigational Drug May Reduce Involuntary Movements in People With Parkinson's Disease

April 12, 2011 12:36 pm | by Bio-Medicine.Org | Comments

HONOLULU, April 12, 2011 /PRNewswire-USNewswire/ -- Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented...

TOPICS:

Changing trends in hip fracture incidence around the world

April 12, 2011 11:42 am | by EurekAlert | Comments

(International Osteoporosis Foundation) A review by a scientific working group of the IOF shows that age-specific hip fracture rates have changed during recent decades -- decreasing in some countries or regions while increasing in others. The review examines some possible reasons...

TOPICS:

BioScale scales up with new MEMS sensor fab cleanrooms, HQ

April 12, 2011 11:41 am | by I-Micronews | Comments

BioScale Inc., a life science company that develops, manufactures, and promotes novel analytical tools enabling advancements in protein research, relocated its corporate headquarters to 4 Maguire Road in Lexington, MA.

Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin

April 12, 2011 11:36 am | by Bio-Medicine.Org | Comments

EAST HANOVER, N.J., April 12, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) tablets for the treatment of patients with...

TOPICS:

MSA Schedules First Quarter Earnings Webcast

April 12, 2011 11:35 am | by Bio-Medicine.Org | Comments

PITTSBURGH, April 12, 2011 /- MSA (NYSE: MSA ), the global leader in the development, manufacture and supply of products that protect people's health and safety, announced today that it will broadcast a first quarter 2011 earnings conference call live via the Internet on Thursday, April...

TOPICS:

Biotech and cystic fibrosis: A kid's view

April 12, 2011 10:42 am | by Mass High Tech: The Journal of New England Technology | Comments

The star of the show was an 8-year-old Red Sox fan from Dedham named Bobby Coughlin, not the 200 globe-trotting investors and accomplished life sciences executives who were both the attendees and speakers at the Boston Biotech Conference. He sat with his father, MassBio president and CEO...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading